Cme Group Stock EBITDA
| MX4A Stock | EUR 228.75 0.10 0.04% |
CME Group fundamentals help investors to digest information that contributes to CME's financial success or failures. It also enables traders to predict the movement of CME Stock. The fundamental analysis module provides a way to measure CME's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CME stock.
CME |
CME Group Company EBITDA Analysis
CME's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current CME EBITDA | 4.02 B |
Most of CME's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CME Group is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, CME Group reported earnings before interest,tax, depreciation and amortization of 4.02 B. This is 93.66% lower than that of the Financial Services sector and 99.25% higher than that of the Financial Exchanges industry. The ebitda for all Germany stocks is 3.0% lower than that of the firm.
CME EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CME's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CME could also be used in its relative valuation, which is a method of valuing CME by comparing valuation metrics of similar companies.CME is currently under evaluation in ebitda category among its peers.
CME Fundamentals
| Return On Equity | 0.0992 | |||
| Return On Asset | 0.0101 | |||
| Profit Margin | 0.54 % | |||
| Operating Margin | 0.60 % | |||
| Current Valuation | 60.85 B | |||
| Shares Outstanding | 359.72 M | |||
| Shares Owned By Insiders | 0.45 % | |||
| Shares Owned By Institutions | 88.31 % | |||
| Price To Earning | 35.53 X | |||
| Price To Book | 2.16 X | |||
| Price To Sales | 12.30 X | |||
| Revenue | 5.02 B | |||
| Gross Profit | 5.01 B | |||
| EBITDA | 4.02 B | |||
| Net Income | 2.69 B | |||
| Cash And Equivalents | 1.02 B | |||
| Cash Per Share | 2.86 X | |||
| Total Debt | 3.42 B | |||
| Debt To Equity | 15.30 % | |||
| Current Ratio | 1.05 X | |||
| Book Value Per Share | 74.89 X | |||
| Cash Flow From Operations | 3.06 B | |||
| Earnings Per Share | 6.98 X | |||
| Price To Earnings To Growth | 4.38 X | |||
| Target Price | 221.47 | |||
| Number Of Employees | 3.46 K | |||
| Beta | 0.41 | |||
| Market Capitalization | 62.87 B | |||
| Total Asset | 174.18 B | |||
| Z Score | 10.8 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.84 % | |||
| Net Asset | 174.18 B | |||
| Last Dividend Paid | 4.0 |
About CME Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CME Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CME using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CME Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in CME Stock
When determining whether CME Group is a strong investment it is important to analyze CME's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CME's future performance. For an informed investment choice regarding CME Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.